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SUMMARY – Acute optic neuritis has the age and sex adjusted incidence of 1-5/100,000 in 
general population. It is mostly a disorder affecting young Caucasian women (31-32 years). Patients 
present to a wide range of clinicians including general practitioner, emergency physician, ophthal-
mologist, neurologist, etc. There are two main clinical presentations of optic neuritis, typical and atyp-
ical. It is of great importance to distinguish these two types of optic neuritis in order to detect the 
underlying etiology and plan appropriate and timely treatment. We present a young female patient (36 
years) admitted to Department of Ophthalmology due to visual loss on the left eye. Magnetic reso-
nance imaging showed demyelinating lesions in frontal and parietal lobe, periventricularly, in mesen-
cephalon and right cerebellar hemisphere, and left optic neuritis; magnetic resonance angiography was 
normal. The patient’s history revealed renal dysfunction, hypothyroidism, and miscarriage in the 6th 
month of pregnancy due to eclampsia, and Fabry disease in family (mother and two sisters). She was 
transferred to the Department of Neurology for further evaluation of the demyelinating disorder of 
the central nervous system. The patient received corticosteroid therapy (methylprednisolone 1 g) for 5 
days with regression of visual disturbances on the left eye. After this acute treatment, the question of 
definitive diagnosis remained, along with further treatment of the underlying cause. Considering renal 
dysfunction, miscarriage, arterial hypertension, positive genetic and biochemical testing for Fabry 
disease in close relatives (mother), we suspected that she also had Fabry disease. She was tested and 
the results were positive. We concluded that optic neuritis was the first sign of Fabry disease in this 
case, reflecting acute atypical neuroinflammatory disease.
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Introduction
Acute optic neuritis has the age and sex adjusted 
incidence of 1-5/100,000 in general population. It is 
mostly a disorder affecting young Caucasian women 
(31-32 years). Patients present to a wide range of clini-
cians including general practitioner, emergency physi-
cian, ophthalmologist, neurologist, etc. There are two 
main clinical presentations of optic neuritis, typical 
and atypical.
In most patients with optic neuritis, the pathology 
is demyelination of the optic nerve, which may reflect 
symptoms of the clinically isolated syndrome sugges-
tive of multiple sclerosis, or be one of the signs of mul-
tiple sclerosis if there is radiological or clinical evi-
dence for brain lesions and clinical symptoms of dis-
semination in space and/or time according to revised 
McDonald criteria for multiple sclerosis. In these pa-
tients, prognosis is good and visual recovery is expect-
ed in 90%-95% of cases. This is a typical form of optic 
neuritis.
Atypical forms of optic neuritis exhibit ‘red flags’ 
for more aggressive etiology and do not recover with-
out directed treatment. It is of great importance to dis-
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tinguish these two types of optic neuritis in order to 
detect the underlying etiology and plan appropriate 
and timely treatment.
Fabry disease is an X-linked inherited lysosomal 
storage disease caused by mutations (or alterations) in 
the a-Gal A (GLA) gene, which result in insufficient 
activity of the a-Gal A enzyme. Lysosomes are pri-
mary digestive units within cells, therefore they are 
enriched with enzymes that break down or digest par-
ticular compounds and intracellular structures. Func-
tion of the GLA enzymes is to break down globotriao-
sylceramide (GL-3 or Gb3), lyso-GL-3/Gb3 and re-
lated glycolipids by removing terminal galactose sugar 
from the end of these glycolipid molecules. The en-
zyme deficiency causes continuous build-up of GL-3/
Gb3 and related glycolipids in body cells, resulting in 
cell abnormalities and organ dysfunction1-3. In females, 
GLA enzyme activity levels depend not only on GLA 
mutations of the X chromosome, but also on the ly-
onization effect4,5.
Fabry disease affects one per 40,000 to 60,000 
males. This disorder also occurs in females, although 
the prevalence is unknown. Milder, late-onset forms of 
the disorder are probably more common than the clas-
sic, severe form. The average age at diagnosis is ap-
proximately 30 years. Delayed diagnosis may be due to 
the rarity of the disease and/or the nonspecific nature 
of its early symptoms6,7.
Symptoms increase with age due to the progressive 
glycolipid accumulation in vascular system, kidneys, 
and heart, leading to kidney failure, heart disease or 
stroke. Involvement of the central nervous system 
(CNS) in Fabry patients is mainly due to cerebral vas-
culopathy affecting both small and large cerebral ves-
sels. Macroangiopathy usually leads to ischemic stroke, 
whereas microangiopathy is usually the cause of pro-
gressive white matter lesions confirmed by magnetic 
resonance imaging (MRI) in about 80% of Fabry pa-
tients (both genders)8,9.
Case Report
We present a young female patient (36 years) ad-
mitted to Department of Ophthalmology due to vi-
sual loss on the left eye (Figs. 1 and 2). MRI showed 
demyelinating lesions in frontal and parietal lobe, peri-
ventricularly, in mesencephalon and right cerebellar 
hemisphere with contrast enhancement (Figs. 3-6), 
and left optic neuritis (Figs. 7 and 8); magnetic reso-
nance angiography was normal. The patient’s history 
revealed renal dysfunction, hypothyroidism, miscar-
riage in the 6th month of pregnancy due to eclampsia 
and genetically confirmed Fabry disease in family 
(mother and 2 sisters). She was transferred to Depart-
ment of Neurology for further neurological evaluation. 
Cerebrospinal fluid evaluation showed mild pleocyto-
sis, normal blood brain barrier function and oligoclo-
nal bands type 3. Visual evoked potentials indicated 
prechiasmal dysfunction of the left optic nerve. Octo-
pus visual field showed normal finding on the right eye 
and decreased RF 10.0 and inferior altitudinal deficit 
within 60 degrees on the left eye. Genetic testing for 
Fabry disease was positive (two heterozygous muta-
tions), with decreased alpha galactosidase activity val-
ues and increased Lyso GB3 values. Neurological ex-
amination showed loss of visual acuity on the left eye, 
without any other neurological signs and symptoms.
The patient received corticosteroid therapy (meth-
ylprednisolone 1 g) for 5 days with regression of visual 
disturbances on the left eye.
According to the radiological and laboratory find-
ings, as well as clinical diagnosis, we concluded that 
the patient probably had Fabry disease with microan-
giopathy complications (autoinflammatory vasculopa-
thy) of the brain white matter and therefore treatment 
with enzyme replacement therapy was introduced. She 
started enzyme replacement therapy in April 2016. 
After 7 months of therapy, she presented clinically 
again with loss of visual acuity of the left eye. Visual 
evoked potentials showed increased latency of the 
P100 waveform and N2 response bilaterally, more pro-
nounced on the left eye. Fundus showed the beginning 
of vascular sclerosis. Octopus visual field of the right 
eye showed normal finding, left eye RF 11.1 and infe-
rior altitudinal deficit within 60 degrees on the left eye. 
Optic nerve and retinal nerve fiber imaging showed a 
decrease of the average retinal nerve fiber layer (RNFL) 
thickness of the left eye (especially decrease of RNFL 
thickness in the temporal lower quadrant of the left 
eye), decrease of vertical thickness of the neuroretinal 
rim of the right eye, as well as decrease of the average 
C/D ratio of the right eye and vertical C/D ratio on 
both eyes. Follow up MRI of the brain and neck 
showed two new small punctiform lesions, one in the 
splenium of the corpus callosum on the left and one 
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subcortically in the left frontal lobe (Figs. 4 and 6) and 
optic neuritis of the left eye (Fig. 8). There was no con-
trast enhancement of parenchymal lesions. The patient 
received corticosteroid therapy (methylprednisolone 1 
g) for 5 days with regression of visual disturbances on 
the left eye.
Fig. 1. Visual evoked potential pattern after 7 months.
Fig. 2. Optic nerve and retinal nerve fiber imaging after 7 months.
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Discussion
Fabry disease affects young people and can develop 
monosymptomatic courses, which only involve CNS 
without any medical history of other classic Fabry 
symptoms such as angiokeratoma, cornea veriticillata, or 
heart and kidney disease. In such cases, atypical optic 
neuritis can be the first and only sign of the disease. It is 
of great importance to distinguish whether it is typical 
optic neuritis as part of multiple sclerosis or atypical op-
tic neuritis as a sign of some other etiology. Differential 
diagnosis of optic neuritis requires detailed workup to 
exclude any other inflammatory or non-inflammatory 
brain white matter diseases, optic nerve compression, 
hereditary diseases (Leber’s hereditary optic neuropa-
thy), nutritional or toxic maculopathies, inflammatory 
or granulomatous causes anti aQ4, anti MOG, sarcoid-
osis, systemic lupus erythematosus, human immunode-
ficiency virus, syphilis, Lyme disease, Bartonella, tuber-
culosis, BehÇet’s syndrome, paraneoplastic retinopathy, 
chronic relapsing inflammatory optic neuritis, storage 
disorders (Fabry disease), etc.
Fig. 3. Horizontal T2 MRI section: 
multiple demyelinating lesions.
Fig. 4. Horizontal T2 MRI section after  
7 months: multiple demyelinating lesions.
Fig. 5. Sagittal T1 MRI section:  
multiple demyelinating lesions.
Fig. 6. Sagittal T1 MRI section after  
7 months: multiple demyelinating lesions.
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Usually, MRI of the cervical spinal cord is not per-
formed in Fabry patients, and lesions at these locations 
are probably underestimated. In most cases, there are 
no white matter lesions in the spinal cord in Fabry pa-
tients, which can be one of the distinguishing param-
eters, but their presence does not exclude the disease; 
in cases of optic neuritis, data on the presence of such 
lesions can give additional information in differential 
diagnostic workup9.
Cerebrospinal fluid changes are also present in 
Fabry patients and are defined as ‘aseptic meningitis’ or 
chronic meningitis with mild to moderate pleocytosis 
(76 cells/μL) and slightly elevated total protein levels 
(up to 800 mg/L) suggesting disturbed blood brain 
barrier function, mostly with lympho-monocytic re-
sponse. Results of postmortem studies showed high 
accumulation of ceramide trihexoside in choroid plex-
us and leptomeninges in Fabry patients. These findings 
suggest an aseptic inflammatory process triggered by 
the stored lipids acting as foreign body stimulus. Oli-
goclonal bands can also be positive in cerebrospinal 
fluid of Fabry patients, they have high sensitivity in 
multiple sclerosis patients, but also are highly unspe-
cific and can occur even after unspecific infections. On 
the other hand, in patients with optic neuritis as the 
only clinical sign of the disease and positive oligoclo-
nal bands, it is hard to distinguish if it is typical optic 
neuritis as part of multiple sclerosis or atypical optic 
neuritis as a sign of some other central nervous system 
disorder10,11.
Good differential diagnosis in the early stages of 
optic neuritis is of great importance for planning long-
term treatment which will cure symptoms and under-
lying condition and prevent organ damage and dis-
abilities. In Fabry patients, enzyme replacement thera-
py has shown good results in disease control. In optic 
neuritis, corticosteroids are the treatment of choice in 
acute phase of the disease. In atypical forms of optic 
neuritis caused by Fabry disease, it is of great impor-
tance to introduce corticosteroid treatment in the 
acute phase of optic neuritis and to plan long-term en-
zyme replacement therapy in order to minimize un-
derlying vascular and changes of choroid plexus and 
leptomeninges due to Gb3 deposits. A combination of 
these treatments will reduce the number of optic neu-
ritis relapses, as well as RNFL (axonal loss) and con-
secutive visual disturbances. In the follow up of optic 
neuritis patients, MRI of the head and neck with con-
trast, visual evoked potentials, visual field, and Optical 
Coherence Tomography Provider Network Opera-
tions (OCT PNO) should be performed in order to 
evaluate activity of the disease, and its morphological 
and functional presentation.
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Sažetak
PONAVLJAJUĆI ATIPIČNI OPTIČKI NEURITIS KAO PRVI ZNAK FABRYJEVE BOLESTI
I. Zavoreo, M. J. Jurašić, M. Lisak, A. Jadrijević Tomas, O. Zrinščak i V. Bašić Kes
Fabryjeva bolest je rijetka X vezana lizosomska bolest nakupljanja koja zahvaća više organskih sustava u organizmu, a u 
središnjem živčanom sustavu (SŽS) se prezentira kao lezije bijele tvari koje su posljedica vaskulopatije i autoimunih procesa 
na razini koroidnog pleksusa. Prikazuje se slučaj mlade žene (36 godina) koja je primljena na našu Kliniku zbog poremećaja 
vida na lijevom oku. Nalaz magnetske rezonance (MR) mozga je pokazao demijelinizacijske lezije u frontalnom i parijetal-
nom režnju, periventrikularno, u mezencefalonu, desnoj hemisferi malog mozga te optički neuritis lijevo. Nalaz MR angio-
grafije mozga je bio uredan. U osobnoj anamnezi se doznaje da se bolesnica liječila zbog bubrežne insuficijencije, hipotireoze 
te da je u 6. mjesecu trudnoće imala spontani pobačaj uslijed eklampsije. U obiteljskoj anamnezi se doznaje da majka boluje 
od Fabryjeve bolesti. U analizi cerebrospinalnog likvora nađe se blaga pleocitoza, uredna funkcija krvnomoždane barijere te 
sinteza IgG unutar SŽS-a, oligoklonske vrpce tip 3. Vidni evocirani potencijali pokazali su disfunkciju prekjazmalno lijevo. 
Genetsko testiranje na Fabryjevu bolest pokazalo je pozitivan nalaz, 2 heterozigotne mutacije, smanjenu aktivnost alfa galak-
tosidaze te povišene vrijednosti Lyso GB3. Bolesnica je primila pulsnu kortikosteroidnu terapiju (metilprednisolon 1 g) kroz 
5 dana na što dolazi do regresije smetnji vida na lijevom oku. Nakon akutnog liječenja simptoma postavlja se pitanje konačne 
dijagnoze i dugoročnog liječenja. Uzimajući u obzir prisutnost bubrežne insuficijencije, eklampsiju u trudnoći uz spontani 
pobačaj, pozitivne rezultate genetskog testiranja i biokemijskih analiza za Fabryjevu bolest te nalaza MR mozga koji opisuje 
promjene dominantno u području stražnje cirkulacije, zaključili smo da će se u bolesnice najvjerojatnije raditi o Fabryjevoj 
bolesti uz autoimune promjene u SŽS-u i da je bolesnicu potrebno liječiti enzimskom nadomjesnom terapijom. S obzirom 
na smetnje vida i nalaze pozitivnih oligoklonskih vrpci koji mogu govoriti i u prilog multiple skleroze potrebno je dalje pra-
titi bolesnicu klinički i neuroradiološki kako bi se postavila definitivna dijagnoza.
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